Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Filament Health and naturally extracted psychedelic medicines, New species of hallucinogenic mushroom discovered in Australia, Psychedelic medicines may ease cancer patients' depression.
COMPASS Pathways and COMP360 psilocybin therapy, The Centre for Mental Health Research and Innovation launches in the UK, Why Dr. Bronner’s is offering ketamine therapy to employees.
Accessing psilocybin in the UK, Inside London's first psychedelic psychotherapy clinic, California activists drop 2022 psilocybin legalisation initiative.
DMT and Major Depressive Disorder, Psilocybin dispensaries operating openly in Vancouver, Johns Hopkins, Yale and New York University collaborate on psychiatrist training.
Two days left for PSYCH Symposium Early Bird Tickets, Novamind to host Phase II psilocybin trial, Demand grows for UK ministers to reclassify psilocybin.
Psychedelic healthcare and PTSD, Study finds few differences between effects of psilocybin and LSD, The regulatory landscape of psychedelic healthcare in Europe is evolving.
Psychedelic profiles: ibogaine; Eleusis goes public via merger, creating a US$450 million company; The future of psychedelic medicine will be drugs you’ve never heard of.
Psychedelic profiles: ketamine; Italian officials certify signatures for psilocybin referendum; Sixty-five per cent of Americans with mental health conditions want access to psychedelics.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.